Aktieanalys

InDex Pharmaceuticals: PK study – positive results - Redeye

Redeye Publicerad: 15 Mar 2023 10:37

Redeye endorses the positive results announced by InDex Pharmaceuticals regarding the PK study in patients with moderate to severe UC, representing a concrete step forward for the company. The study confirmed the 500mg dose of cobitolimod was well-tolerated with no adverse events and limited systemic uptake. We also note (acknowledging the limited sample size) that four out of seven patients achieved clinical remission at week six. We emphasize the conspicuously low valuation of InDex shares, which despite today's 10% bounce, trades at a negative EV. We reiterate our SEK1.8 base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/889677/index-pharmaceuticals-pk-study-positive-results?utm_source=finwire&utm_medium=RSS

Nyheter om Flerie

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!